Drug Watch

Compounds in Development for Chronic Hepatitis B

Updated December 2016

 

FAMILY/DRUG NAME

 

 

MECHANISM

 

COMPANY

 

WEBSITE


USA STATUS

Interferons: Mimic infection-fighting immune substances naturally produced in the body.

Intron A (Interferon alfa-2b)

Immunomodulator

Merck, USA

merck.com

Approved 1991

Pegasys (Peginterferon alfa-2a)

Immunomodulator

Genentech, USA

gene.com

Approved 2005


Nucleos(t)ide Analogues: Interfere with viral DNA polymerase used for HBV replication 

Epivir (Lamivudine)

Inhibits viral DNA polymerase

GlaxoSmithKline (GSK)

gsk.com

Approved 1998

Hepsera (Adefovir dipivoxil)

Inhibits viral DNA polymerase

Gilead Sciences, USA

gilead.com

Approved 2002

Baraclude (Entecavir)

Inhibits viral DNA polymerase

Bristol-Myers Squibb, USA

bms.com

Approved 2005

Tyzeka (Telbivudine)

Inhibits viral DNA polymerase

Novartis, USA

novartis.com

Approved 2006

Viread (Tenofovir)

Inhibits viral DNA polymerase

Gilead Sciences

gilead.com

Approved 2008

Vemlidy (Tenofovir alafenamide/TAF)

Prodrug of tenofovir

Gilead Sciences

gilead.com 

Approved Nov. 2016

Levovir (Clevudine)

Inhibits viral DNA polymerase

Bukwang, S. Korea

bukwang.co.kr

Approved 2006 in S. Korea

Zadaxin 

Immunomodulator

SciClone, USA

sciclone.com

Approved outside USA

 

DIRECT ACTING ANTIVIRALS: Targets the virus and interferes in the HBV replication process 

 

TDF Pro Drugs: A modified tenofovir drug that can get into liver cells more easily

CMX 157

Prodrug of tenofovir

ContraVir, USA

 

contravir.com

Phase II

 

Silencing RNA’s (siRNAs): Interferes and destroys viral RNA

ARB-1467

RNAi gene silencer (1.0)

Arbutus Biopharma, Canada

arbutusbio.com

Phase II

ALN-HBV

RNAi gene silencer

Alnylam, USA

alnylam.com

Preclinical

Hepbarna (BB-HB-331)

RNAi gene silencer

Benitec, Australia

benitec.com

Preclinical

ARB-1740

RNAi gene silencer (2.0)

Arbutus Biopharma

arbutusbio.com

Preclinical

Lunar-HBV

RNAi gene silencer

Arcturus, USA with Janssen of J&J

arcturusrx.com

Preclinical

 

Entry Inhibitors: Interferes with HBV getting into liver cells

Myrcludex B

Entry inhibitor

Hepatera, Russia with MYR GmbH, Germany

myr-pharma.com

Phase II

 

Capsid Inhibitors: Interferes with the viral DNA protein shield

Morphothiadin (GLS4)

Capsid inhibitor

HEC Pharma,
PR China

pharm.hec.cn/en

Phase II

NVR 3-778

Capsid inhibitor

Janssen of J&J

janssen.com

Phase II

AIC 649

Capsid inhibitor

AiCuris, Germany

aicuris.com

Phase I

JNJ56136379

Capsid Inhibitor

Janssen of J&J

janssen.com

Phase I

HBV CpAM

Capsid inhibitor

Assembly Biosciences, USA

assemblybio.com

Preclinical

AB-423

Capsid inhibitor

Arbutus Biopharma

arbutusbio.com

Preclinical

 

HBsAg Inhibitors: Interferes with production of HBV surface antigen (sAg)

Rep 2139

sAg inhibitor

REPLICor, Canada

replicor.com

Phase II

Rep 2165

sAg inhibitor

REPLICor

replicor.com

Phase II

RO7020322 (RG7834)

sAg inhibitor

Roche

roche.com

Phase I

 

Antisense Molecules: Binds to the viral mRNA to prevent it from turning into viral protein

IONIS-HBVRx (GSK3228836)

Viral protein inhibitor

Ionis Pharma, USA with GSK

ionispharma.com

Phase I

IONIS-HBVLRx (GSK33389404)

Viral protein inhibitor

Ionis Pharma with GSK

ionispharma.com

Phase I

 

INDIRECT ACTING ANTIVIRALS: Targets the human immune system to attack the HBV virus

 

Therapeutic Vaccines: Vaccine technology used to stimulate the immune system as a treatment 

GS 4774

Therapeutic vaccine

Gilead with GlobeImmune, USA

gilead.com

Phase II

INO-1800

Therapeutic vaccine

Inovio, USA

inovio.com

Phase I

HB-110

Therapeutic vaccine

Ichor, USA with Janssen

ichorms.com

Phase I

TG1050

Therapeutic vaccine

Transgene, France

transgene.com

Phase I

HepTcell

Therapeutic vaccine

Altimmune, USA

altimmune.com

Phase I

TomegaVax HBV

Therapeutic vaccine

TomegaVax, USA

tomegavax.com

Preclinical

 

Innate Immune Defense Pathway: Compounds that activate the innate immune system 

GS 9620

TLR-7 agonist

Gilead Sciences

gilead.com

Phase II

RO6864018 (RG7795, ANA773)

TLR-7 agonist

Roche

roche.com

Phase II

SB9200

RIG -1 and NOD2 agonist

Spring Bank Pharmaceuticals, USA

springbankpharm.com

Phase II

 

Host Acting Pathway: Compounds that induce programmed cell death (apoptosis)

EYP001

FXR agonist

Enyo Pharma, France

enyopharma.com

Phase I

CRV 431 (CPI 431-32)

Ciclofillin inhibitor

ContraVir

contravir.com

Preclinical

 

HEPATITIS DELTA VIRUS (HDV)

Myrcludex B

Entry inhibitor

MYR-GmbH

myr-pharma.com

Phase II

Lonafarnib

Prenylation inhibitor

Eiger Biopharma, USA

eigerbio.com

Phase II

Pegylated Interferon Lambda

Immunomodulator

Eiger Biopharma, USA

eigerbio.com

Phase II

Rep 2139

HBsAg inhibitor

REPLICor

replicor.com

Phase II

ALN-HDV

RNAi gene silencer

Alnylam

alnylam.com

Preclinical